PD-L1 blockade enhances anti-tumor efficacy of NK cells

Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Oyer, Jeremiah L., Gitto, Sarah B., Altomare, Deborah A., Copik, Alicja J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205063/
https://ncbi.nlm.nih.gov/pubmed/30377572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1509819
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia